BioCryst estimates $6.2-7.5M in severance costs for discovery program discontinuation

BIOCRYST PHARMACEUTICALS INC

Plan to discontinue internal discovery programs and close Birmingham, AL facility announced June 29, 2026.
One-time expenses of $6.2-7.5M for employee termination benefits and severance; $5.3-6.6M cash expenditures.
Facility closure costs (contract/lease termination, asset impairment) not yet estimable; further filing expected.
Restructuring part of strategic evolution to strengthen rare disease pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.